Sphingolipids in the Pathogenesis of Parkinson’s Disease and Parkinsonism

The pathogenic mechanisms underlying Parkinson's disease (PD)/parkinsonism affect mitochondrial and endolysosomal trafficking. The retromer is required to retrieve some proteins from endosomes to the Golgi and plasma membrane. Here, we discuss how retromer-dependent retrieval also affects ceramide metabolism. Compelling studies across PD models in Drosophila and mammalian neurons reveal a pathogenic cascade implicating retromer dysfunction and mitochondrial defects. We argue that ceramides may play a critical role in the pathobiology based on the studies of PLA2G6 and VPS35 in Drosophila mutants and human knock-down cells. In addition, pathogenic variants in many lysosomal storage disorder genes have recently been associated with PD, suggesting a potential overlap between the pathogenic mechanisms underlying these disorders. We propose that disruption of ceramide metabolism may affect endolysosomal and mitochondrial function, and plays an important role in PD/parkinsonism.

[1]  Armin Giese,et al.  Inhibition of mitochondrial fusion by α‐synuclein is rescued by PINK1, Parkin and DJ‐1 , 2010, The EMBO journal.

[2]  Sohee Jeon,et al.  Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease , 2017, Science.

[3]  A. Whitworth,et al.  VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin , 2015, Human molecular genetics.

[4]  L. Polito,et al.  Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's Disease , 2016, Parkinson's disease.

[5]  L. Bubacco,et al.  LRRK2 deficiency impacts ceramide metabolism in brain. , 2016, Biochemical and biophysical research communications.

[6]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[7]  J. Jankovic,et al.  Parkinsonism, movement disorders and genetics in frontotemporal dementia , 2016, Nature Reviews Neurology.

[8]  D. Berg,et al.  Plasma Ceramide and Glucosylceramide Metabolism Is Altered in Sporadic Parkinson's Disease and Associated with Cognitive Impairment: A Pilot Study , 2013, PloS one.

[9]  Wenzhang Wang,et al.  Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes , 2015, Nature Medicine.

[10]  D. Krainc,et al.  α-Synuclein–induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models , 2016, Proceedings of the National Academy of Sciences.

[11]  J. Allman,et al.  Neuropathology provides clues to the pathophysiology of Gaucher disease. , 2004, Molecular genetics and metabolism.

[12]  D. Krainc,et al.  Deficiency of ATP13A2 Leads to Lysosomal Dysfunction, α-Synuclein Accumulation, and Neurotoxicity , 2012, The Journal of Neuroscience.

[13]  G. Sobue,et al.  Extensive aggregation of α-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site , 2013, Acta neuropathologica communications.

[14]  D. Perl,et al.  Acid sphingomyelinase deficient mice: a model of types A and B Niemann–Pick disease , 1995, Nature Genetics.

[15]  J. Shulman,et al.  Uncoupling neuronal death and dysfunction in Drosophila models of neurodegenerative disease , 2016, Acta neuropathologica communications.

[16]  B. Ogretmen,et al.  Ceramide induced mitophagy and tumor suppression. , 2015, Biochimica et biophysica acta.

[17]  John Hardy,et al.  Parkinson's disease , 2009, The Lancet.

[18]  Masaki Tanaka,et al.  Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous α-synuclein fibrils , 2015, Neurobiology of Disease.

[19]  Jennifer C. Lee,et al.  α-Synuclein Interacts with Glucocerebrosidase Providing a Molecular Link between Parkinson and Gaucher Diseases* , 2011, The Journal of Biological Chemistry.

[20]  A. Schapira,et al.  Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Disease—Links to Parkinson’s Disease , 2013, Cell metabolism.

[21]  D. Krainc,et al.  Parkin Modulates Endosomal Organization and Function of the Endo-Lysosomal Pathway , 2016, Journal of Neuroscience.

[22]  L. Partridge,et al.  A Drosophila Model of Neuronopathic Gaucher Disease Demonstrates Lysosomal-Autophagic Defects and Altered mTOR Signalling and Is Functionally Rescued by Rapamycin , 2016, The Journal of Neuroscience.

[23]  R. Boot,et al.  Lysosomal glycosphingolipid catabolism by acid ceramidase: formation of glycosphingoid bases during deficiency of glycosidases , 2016, FEBS letters.

[24]  H. Christian,et al.  ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons , 2016, Stem cell reports.

[25]  S. Chandra,et al.  Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease , 2017, The Journal of Neuroscience.

[26]  S. D. de Jager,et al.  Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death , 2015, Human molecular genetics.

[27]  J. Hardy,et al.  Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction , 2015, Brain : a journal of neurology.

[28]  L. Wrabetz,et al.  Altered Trafficking and Processing of GALC Mutants Correlates with Globoid Cell Leukodystrophy Severity , 2016, The Journal of Neuroscience.

[29]  M. Nalls,et al.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.

[30]  Christer S. Ejsing,et al.  The GARP complex is required for cellular sphingolipid homeostasis , 2015, eLife.

[31]  Simon C. Potter,et al.  Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease , 2017, Brain : a journal of neurology.

[32]  Silva Hecimovic,et al.  Loss of Cathepsin B and L Leads to Lysosomal Dysfunction, NPC-Like Cholesterol Sequestration and Accumulation of the Key Alzheimer's Proteins , 2016, PloS one.

[33]  H. Mortiboys,et al.  Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2 , 2010, Neurology.

[34]  RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. , 2013, Neuron.

[35]  Nele A. Haelterman,et al.  A mitocentric view of Parkinson's disease. , 2014, Annual review of neuroscience.

[36]  P. Lockhart,et al.  The emerging role of Rab GTPases in the pathogenesis of Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[37]  M. Maffia,et al.  Lipid profiling of parkin‐mutant human skin fibroblasts , 2017, Journal of cellular physiology.

[38]  M. Haque,et al.  Silencing of Glucocerebrosidase Gene in Drosophila Enhances the Aggregation of Parkinson's Disease Associated α-Synuclein Mutant A53T and Affects Locomotor Activity , 2018, Front. Neurosci..

[39]  R. Nussbaum,et al.  Direct Membrane Association Drives Mitochondrial Fission by the Parkinson Disease-associated Protein α-Synuclein*♦ , 2011, The Journal of Biological Chemistry.

[40]  M. Nalls,et al.  A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.

[41]  A. Whitworth,et al.  Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models , 2016, Scientific Reports.

[42]  A. Pandey,et al.  GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers , 2018, Proceedings of the National Academy of Sciences.

[43]  P. Calabresi,et al.  Lysosomal Dysfunction and α‐Synuclein Aggregation in Parkinson's Disease: Diagnostic Links , 2016, Movement disorders : official journal of the Movement Disorder Society.

[44]  A. Gregory,et al.  Neurodegeneration with brain iron accumulation. , 2005, Folia neuropathologica.

[45]  Xiao-Min Wang,et al.  GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A , 2015, Autophagy.

[46]  C. Gieger,et al.  The role of SCARB2 as susceptibility factor in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[47]  G. Petsko,et al.  Pharmacological chaperones stabilize retromer to limit APP processing. , 2014, Nature chemical biology.

[48]  Tianhong Pan,et al.  The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. , 2008, Brain : a journal of neurology.

[49]  S. Berkovic,et al.  Abnormal Processing of Autophagosomes in Transformed B Lymphocytes from SCARB2-Deficient Subjects , 2013, BioResearch open access.

[50]  S. Lindquist,et al.  α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models , 2006, Science.

[51]  Elie Needle,et al.  Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression. , 2015, Human molecular genetics.

[52]  N. Avadhani,et al.  Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain* , 2008, Journal of Biological Chemistry.

[53]  S.-J. Lee,et al.  Haploinsufficiency of cathepsin D leads to lysosomal dysfunction and promotes cell-to-cell transmission of α-synuclein aggregates , 2015, Cell Death and Disease.

[54]  Jan Gründemann,et al.  Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase , 2006, Nature Genetics.

[55]  D. Vassilatis,et al.  Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[56]  Jennifer C. Lee,et al.  Cysteine cathepsins are essential in lysosomal degradation of α-synuclein , 2015, Proceedings of the National Academy of Sciences.

[57]  Peng Wang,et al.  The genetics of Parkinson disease , 2018, Ageing Research Reviews.

[58]  G. Rubboli,et al.  SCARB2/LIMP2 deficiency in action myoclonus-renal failure syndrome. , 2016, Epileptic disorders : international epilepsy journal with videotape.

[59]  P. Hogarth,et al.  Neurodegeneration with Brain Iron Accumulation , 2004 .

[60]  A. Takeda,et al.  VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson's disease , 2014, Neurobiology of Disease.

[61]  C. Nüsslein-Volhard,et al.  Live Imaging of Neuronal Degradation by Microglia Reveals a Role for v0-ATPase a1 in Phagosomal Fusion In Vivo , 2008, Cell.

[62]  J. Harper,et al.  Building and decoding ubiquitin chains for mitophagy , 2018, Nature Reviews Molecular Cell Biology.

[63]  J. Hardy,et al.  Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.

[64]  M. Brini,et al.  The Close Encounter Between Alpha-Synuclein and Mitochondria , 2018, Front. Neurosci..

[65]  Susan E. Brockerhoff,et al.  Synaptojanin 1 Is Required for Endolysosomal Trafficking of Synaptic Proteins in Cone Photoreceptor Inner Segments , 2014, PloS one.

[66]  R. Gershoni-baruch,et al.  The contribution of Niemann-Pick SMPD1 mutations to Parkinson disease in Ashkenazi Jews. , 2015, Parkinsonism & related disorders.

[67]  K. Venderová,et al.  Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson’s disease mutant of Leucine-rich repeat kinase 2 (LRRK2) , 2014, Molecular Neurodegeneration.

[68]  T. Dawson,et al.  Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes , 2017, Experimental Neurology.

[69]  D. Sulzer,et al.  Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra Neurons , 2009, Neuron.

[70]  H. McBride,et al.  Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control , 2014, The EMBO journal.

[71]  E. Masliah,et al.  Protective role of endogenous gangliosides for lysosomal pathology in a cellular model of synucleinopathies. , 2009, The American journal of pathology.

[72]  H. Ko,et al.  D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model , 2018, Acta Neuropathologica Communications.

[73]  K. Marder,et al.  RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk , 2013, Neuron.

[74]  J. Ferreira,et al.  Serum lipid alterations in GBA-associated Parkinson's disease. , 2017, Parkinsonism & related disorders.

[75]  A. F. Schinder,et al.  αSynuclein control of mitochondrial homeostasis in human-derived neurons is disrupted by mutations associated with Parkinson’s disease , 2017, Scientific Reports.

[76]  P. Boya,et al.  High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A , 2014, Cell Death and Differentiation.

[77]  M. Farrer,et al.  LRRK2 mutations in Parkinson disease , 2005, Neurology.

[78]  Sarah C. Izen,et al.  Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice , 2015, Antioxidants & redox signaling.

[79]  S. Sardi,et al.  Modulation of &bgr;-glucocerebrosidase increases &agr;-synuclein secretion and exosome release in mouse models of Parkinson’s disease , 2018, Human molecular genetics.

[80]  H. Bellen,et al.  The retromer complex in development and disease , 2015, Development.

[81]  Ying Sun,et al.  Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies , 2011, Cell.

[82]  H. Bellen,et al.  Correction: The Retromer Complex Is Required for Rhodopsin Recycling and Its Loss Leads to Photoreceptor Degeneration , 2015, PLoS biology.

[83]  M. Cookson,et al.  LRRK2 at the interface of autophagosomes, endosomes and lysosomes , 2016, Molecular Neurodegeneration.

[84]  S. Lindquist,et al.  α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity , 2009, Nature Genetics.

[85]  E. Schuchman,et al.  Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. , 1997, Genetic testing.

[86]  J. Bronstein,et al.  Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity , 2014, Disease Models & Mechanisms.

[87]  H. Bellen,et al.  Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to α-Synuclein Gain. , 2018, Cell metabolism.